FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000457925> ?p ?o ?g. }

• W2000457925 endingPage "976" @default.
• W2000457925 startingPage "971" @default.
• W2000457925 abstract "Efficacy and safety are the two considerations when characterising the effects of a new therapy. We sought to apply an innovative method of assessing the benefit-risk balance using data from a completed randomised controlled trial that compared erlotinib vs placebo added to gemcitabine in patients with advanced pancreatic cancer (NCIC CTG PA.3).We applied generalised pairwise comparisons with several prioritised outcome measures (e.g., one or more benefit outcomes and one or more risk outcomes). Here, the first priority outcome was overall survival (OS) time. Differences in OS that exceeded 2 months were considered clinically meaningful. The second priority outcome was toxicity. The overall treatment effect was quantified using the proportion in favour of erlotinib, which can be interpreted as the net proportion of patients who have a better overall outcome with erlotinib as compared with placebo. Sensitivity analyses were performed.In this trial 569 patients were randomly assigned in a 1 : 1 ratio to receive gemcitabine plus either erlotinib or a matched placebo. Overall, the method indicated no statistically significant overall treatment effect in favour of erlotinib; if anything, the point estimate of the net proportion leaned in favour of the placebo group (overall proportion in favour of erlotinib=-3.6%, 95% CI, -14.2- 7.1%; P=0.51). The net proportion was never in favour of the erlotinib group throughout all sensitivity analyses.Generalised pairwise comparisons make it possible to assess the benefit-risk balance of new treatments using a single statistical test for any number of prioritised outcomes. The benefit-risk assessment was not in favour of adding erlotinib to gemcitabine for the treatment of patients with advanced pancreatic cancer." @default.
• W2000457925 created "2016-06-24" @default.
• W2000457925 creator A5001985433 @default.
• W2000457925 creator A5002916492 @default.
• W2000457925 creator A5054799901 @default.
• W2000457925 creator A5064939755 @default.
• W2000457925 creator A5076283364 @default.
• W2000457925 creator A5085474533 @default.
• W2000457925 date "2015-02-17" @default.
• W2000457925 modified "2023-10-08" @default.
• W2000457925 title "Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer" @default.
• W2000457925 cites W1585504346 @default.
• W2000457925 cites W1931508686 @default.
• W2000457925 cites W1965542961 @default.
• W2000457925 cites W1986360186 @default.
• W2000457925 cites W1992165995 @default.
• W2000457925 cites W1996198481 @default.
• W2000457925 cites W2016044915 @default.
• W2000457925 cites W2025140953 @default.
• W2000457925 cites W2034790774 @default.
• W2000457925 cites W2099456211 @default.
• W2000457925 cites W2105909603 @default.
• W2000457925 cites W2109506970 @default.
• W2000457925 cites W2135656951 @default.
• W2000457925 cites W2144602735 @default.
• W2000457925 cites W2148370712 @default.
• W2000457925 cites W2151253787 @default.
• W2000457925 cites W2158134441 @default.
• W2000457925 cites W2290126718 @default.
• W2000457925 cites W2410090482 @default.
• W2000457925 doi "https://doi.org/10.1038/bjc.2015.55" @default.
• W2000457925 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4366896" @default.
• W2000457925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25688740" @default.
• W2000457925 hasPublicationYear "2015" @default.
• W2000457925 type Work @default.
• W2000457925 sameAs 2000457925 @default.
• W2000457925 citedByCount "25" @default.
• W2000457925 countsByYear W20004579252015 @default.
• W2000457925 countsByYear W20004579252016 @default.
• W2000457925 countsByYear W20004579252017 @default.
• W2000457925 countsByYear W20004579252019 @default.
• W2000457925 countsByYear W20004579252020 @default.
• W2000457925 countsByYear W20004579252021 @default.
• W2000457925 countsByYear W20004579252022 @default.
• W2000457925 countsByYear W20004579252023 @default.
• W2000457925 crossrefType "journal-article" @default.
• W2000457925 hasAuthorship W2000457925A5001985433 @default.
• W2000457925 hasAuthorship W2000457925A5002916492 @default.
• W2000457925 hasAuthorship W2000457925A5054799901 @default.
• W2000457925 hasAuthorship W2000457925A5064939755 @default.
• W2000457925 hasAuthorship W2000457925A5076283364 @default.
• W2000457925 hasAuthorship W2000457925A5085474533 @default.
• W2000457925 hasBestOaLocation W20004579251 @default.
• W2000457925 hasConcept C105795698 @default.
• W2000457925 hasConcept C121608353 @default.
• W2000457925 hasConcept C126322002 @default.
• W2000457925 hasConcept C142724271 @default.
• W2000457925 hasConcept C143998085 @default.
• W2000457925 hasConcept C168563851 @default.
• W2000457925 hasConcept C184898388 @default.
• W2000457925 hasConcept C204787440 @default.
• W2000457925 hasConcept C27081682 @default.
• W2000457925 hasConcept C2778087573 @default.
• W2000457925 hasConcept C2779438470 @default.
• W2000457925 hasConcept C2780210213 @default.
• W2000457925 hasConcept C2780258809 @default.
• W2000457925 hasConcept C2909325608 @default.
• W2000457925 hasConcept C33923547 @default.
• W2000457925 hasConcept C71924100 @default.
• W2000457925 hasConceptScore W2000457925C105795698 @default.
• W2000457925 hasConceptScore W2000457925C121608353 @default.
• W2000457925 hasConceptScore W2000457925C126322002 @default.
• W2000457925 hasConceptScore W2000457925C142724271 @default.
• W2000457925 hasConceptScore W2000457925C143998085 @default.
• W2000457925 hasConceptScore W2000457925C168563851 @default.
• W2000457925 hasConceptScore W2000457925C184898388 @default.
• W2000457925 hasConceptScore W2000457925C204787440 @default.
• W2000457925 hasConceptScore W2000457925C27081682 @default.
• W2000457925 hasConceptScore W2000457925C2778087573 @default.
• W2000457925 hasConceptScore W2000457925C2779438470 @default.
• W2000457925 hasConceptScore W2000457925C2780210213 @default.
• W2000457925 hasConceptScore W2000457925C2780258809 @default.
• W2000457925 hasConceptScore W2000457925C2909325608 @default.
• W2000457925 hasConceptScore W2000457925C33923547 @default.
• W2000457925 hasConceptScore W2000457925C71924100 @default.
• W2000457925 hasIssue "6" @default.
• W2000457925 hasLocation W20004579251 @default.
• W2000457925 hasLocation W20004579252 @default.
• W2000457925 hasLocation W20004579253 @default.
• W2000457925 hasLocation W20004579254 @default.
• W2000457925 hasLocation W20004579255 @default.
• W2000457925 hasLocation W20004579256 @default.
• W2000457925 hasOpenAccess W2000457925 @default.
• W2000457925 hasPrimaryLocation W20004579251 @default.
• W2000457925 hasRelatedWork W2057074797 @default.
• W2000457925 hasRelatedWork W2084590458 @default.
• W2000457925 hasRelatedWork W2168849655 @default.
• W2000457925 hasRelatedWork W2303571720 @default.

• next